SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

20 Oct 2022 Evaluate
The Revenue for the quarter ended  September 2022 of Rs. 3553.69 millions grew by 10.14 % from Rs. 3226.61 millions.A slender decline of -3.77% was recorded to Rs. 1151.97  millions from Rs. 1197.08 millions in the corresponding previous quarter.OP of the company witnessed a marginal growth to 1472.01 millions from 1446.98 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 3553.69 3226.61 10.14 6841.29 6289.57 8.77 12157.30 11088.34 9.64
Other Income 61.53 76.54 -19.61 95.25 141.01 -32.45 289.89 99.98 189.95
PBIDT 1472.01 1446.98 1.73 2767.60 2736.89 1.12 5129.84 4273.12 20.05
Interest 74.86 7.86 852.42 147.12 12.49 1077.90 29.91 7.78 284.45
PBDT 1397.15 1439.12 -2.92 2620.48 2724.40 -3.81 5099.93 4265.34 19.57
Depreciation 159.04 116.19 36.88 308.76 228.48 35.14 514.55 376.40 36.70
PBT 1238.11 1322.93 -6.41 2311.72 2495.92 -7.38 4585.38 3888.94 17.91
TAX 86.14 125.85 -31.55 203.84 231.64 -12.00 413.46 382.89 7.98
Deferred Tax -122.56 -163.79 -25.17 -198.80 -266.21 -25.32 -388.26 -318.95 21.73
PAT 1151.97 1197.08 -3.77 2107.88 2264.28 -6.91 4171.92 3506.05 18.99
Equity 135.99 135.91 0.06 135.99 135.91 0.06 135.93 135.78 0.11
PBIDTM(%) 41.42 44.85 -7.63 40.45 43.51 -7.03 42.20 38.54 9.49

Eris Lifesciences Share Price

1432.95 -13.55 (-0.94%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×